These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 36841050)
1. Design, synthesis, and evaluation of hydrazones as dual inhibitors of ryanodine receptors and acetylcholinesterases for Alzheimer's disease. Yang F; Zhao J; Chen G; Han H; Hu S; Wang N; Wang J; Chen Y; Zhou Z; Dai B; Hou Y; Liu Y Bioorg Chem; 2023 Apr; 133():106432. PubMed ID: 36841050 [TBL] [Abstract][Full Text] [Related]
2. Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease. Fernandes TB; Cunha MR; Sakata RP; Candido TM; Baby AR; Tavares MT; Barbosa EG; Almeida WP; Parise-Filho R Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28940630 [TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological activity of novel semicarbazones as potent Ryanodine receptor1 inhibitors of Alzheimer's disease. Dai B; Ma X; Tang Y; Xu L; Guo S; Chen X; Lu S; Wang G; Liu Y Bioorg Med Chem; 2021 Jan; 29():115891. PubMed ID: 33278783 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and biological evaluation of novel donepezil-tacrine hybrids as multi-functional agents with low neurotoxicity against Alzheimer's disease. Wang N; Jia W; Wang J; Yang Z; Liu Y; Huang D; Mei X; Xiong X; Shi J; Tang Y; Chen G; Di D; Hou Y; Liu Y Bioorg Chem; 2024 Feb; 143():107010. PubMed ID: 38056387 [TBL] [Abstract][Full Text] [Related]
5. Bioactive sulfonyl hydrazones with alkyl derivative: Characterization, ADME properties, molecular docking studies and investigation of inhibition on choline esterase enzymes for the diagnosis of Alzheimer's disease. Bilen E; Özdemir Özmen Ü; Çete S; Alyar S; Yaşar A Chem Biol Interact; 2022 Jun; 360():109956. PubMed ID: 35452634 [TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease. Hu J; Huang YD; Pan T; Zhang T; Su T; Li X; Luo HB; Huang L ACS Chem Neurosci; 2019 Jan; 10(1):537-551. PubMed ID: 30252439 [TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: Discovery of novel multi-target anti-alzheimer prototype drug candidates. Dias Viegas FP; de Freitas Silva M; Divino da Rocha M; Castelli MR; Riquiel MM; Machado RP; Vaz SM; Simões de Lima LM; Mancini KC; Marques de Oliveira PC; Morais ÉP; Gontijo VS; da Silva FMR; D'Alincourt da Fonseca Peçanha D; Castro NG; Neves GA; Giusti-Paiva A; Vilela FC; Orlandi L; Camps I; Veloso MP; Leomil Coelho LF; Ionta M; Ferreira-Silva GÁ; Pereira RM; Dardenne LE; Guedes IA; de Oliveira Carneiro Junior W; Quaglio Bellozi PM; Pinheiro de Oliveira AC; Ferreira FF; Pruccoli L; Tarozzi A; Viegas C Eur J Med Chem; 2018 Mar; 147():48-65. PubMed ID: 29421570 [TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors. Lan JS; Zhang T; Liu Y; Yang J; Xie SS; Liu J; Miao ZY; Ding Y Eur J Med Chem; 2017 Jun; 133():184-196. PubMed ID: 28388521 [TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis, and Biological Evaluation of Orally Available First-Generation Dual-Target Selective Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 5 (PDE5) for the Treatment of Alzheimer's Disease. Mao F; Wang H; Ni W; Zheng X; Wang M; Bao K; Ling D; Li X; Xu Y; Zhang H; Li J ACS Chem Neurosci; 2018 Feb; 9(2):328-345. PubMed ID: 29068218 [TBL] [Abstract][Full Text] [Related]
10. Design, molecular Docking, synthesis and evaluation of xanthoxylin hybrids as dual inhibitors of IL-6 and acetylcholinesterase for Alzheimer's disease. Kaur S; Bansal Y Bioorg Chem; 2022 Apr; 121():105670. PubMed ID: 35189442 [TBL] [Abstract][Full Text] [Related]
11. 6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease. Zueva IV; Semenov VE; Mukhamedyarov MA; Lushchekina SV; Kharlamova AD; Petukhova EO; Mikhailov AS; Podyachev SN; Saifina LF; Petrov KA; Minnekhanova OA; Zobov VV; Nikolsky EE; Masson P; Reznik VS Int J Risk Saf Med; 2015; 27 Suppl 1():S69-71. PubMed ID: 26639718 [TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase. Wang DM; Feng B; Fu H; Liu AL; Wang L; Du GH; Wu S Molecules; 2017 Jan; 22(1):. PubMed ID: 28117700 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease. Rodríguez-Lavado J; Gallardo-Garrido C; Mallea M; Bustos V; Osorio R; Hödar-Salazar M; Chung H; Araya-Maturana R; Lorca M; Pessoa-Mahana CD; Mella-Raipán J; Saitz C; Jaque P; Reyes-Parada M; Iturriaga-Vásquez P; Pessoa-Mahana H Eur J Med Chem; 2020 Jul; 198():112368. PubMed ID: 32388114 [TBL] [Abstract][Full Text] [Related]
14. Rational design and biological evaluation of a new class of thiazolopyridyl tetrahydroacridines as cholinesterase and GSK-3 dual inhibitors for Alzheimer's disease. Jiang X; Zhou J; Wang Y; Chen L; Duan Y; Huang J; Liu C; Chen Y; Liu W; Sun H; Feng F; Qu W Eur J Med Chem; 2020 Dec; 207():112751. PubMed ID: 32950908 [TBL] [Abstract][Full Text] [Related]
15. A Series of New Hydrazone Derivatives: Synthesis, Molecular Docking and Anticholinesterase Activity Studies. Bozbey İ; Özdemir Z; Uslu H; Özçelik AB; Şenol FS; Orhan İE; Uysal M Mini Rev Med Chem; 2020; 20(11):1042-1060. PubMed ID: 31660824 [TBL] [Abstract][Full Text] [Related]
16. Ultrasound-Assisted Synthesis of Piperidinyl-Quinoline Acylhydrazones as New Anti-Alzheimer's Agents: Assessment of Cholinesterase Inhibitory Profile, Molecular Docking Analysis, and Drug-like Properties. Munir R; Zaib S; Zia-Ur-Rehman M; Hussain N; Chaudhry F; Younas MT; Zahra FT; Tajammul Z; Javid N; Dera AA; Ogaly HA; Khan I Molecules; 2023 Feb; 28(5):. PubMed ID: 36903376 [TBL] [Abstract][Full Text] [Related]
17. Hydrazone-sulfonate hybrids as potential cholinesterase inhibitors: design, synthesis and molecular modeling simulation. Omar MA; El-Shiekh RA; Dawood DH; Temirak A; Srour AM Future Med Chem; 2023 Dec; 15(24):2269-2287. PubMed ID: 37994559 [No Abstract] [Full Text] [Related]
18. New phosphazine and phosphazide derivatives as multifunctional ligands targeting acetylcholinesterase and β-Amyloid aggregation for treatment of Alzheimer's disease. El-Sayed NF; El-Hussieny M; Ewies EF; Fouad MA; Boulos LS Bioorg Chem; 2020 Jan; 95():103499. PubMed ID: 31838287 [TBL] [Abstract][Full Text] [Related]
19. Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer's action: Design, synthesis, crystal structure and in-vitro biological evaluation. Manzoor S; Prajapati SK; Majumdar S; Raza MK; Gabr MT; Kumar S; Pal K; Rashid H; Kumar S; Krishnamurthy S; Hoda N Eur J Med Chem; 2021 Apr; 215():113224. PubMed ID: 33582578 [TBL] [Abstract][Full Text] [Related]
20. Novel Pyridine-Containing Sultones: Structure-Activity Relationship and Biological Evaluation as Selective AChE Inhibitors for the Treatment of Alzheimer's disease. Zhang H; Wu C; Chen X; Zhang Z; Jiang X; Qin HL; Tang W ChemMedChem; 2021 Oct; 16(20):3189-3200. PubMed ID: 34036731 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]